C4 Therapeutics, Inc.
CCCCNasdaq
$3.69
↑ +3.1%Jul 17 close · end-of-day
Price
1Y↑ +82.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$465.2M
Enterprise Value
$403.9M
P/E
—
P/S
13.3
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
-20.6%
Dividend Yield
—
Revenue (TTM)
$34.9M
Net Income (TTM)
-$103.8M
Free Cash Flow (TTM)
-$96.0M
Gross Margin
—
Operating Margin
-326.6%
Net Margin
-297.8%
ROE
-44.3%
ROIC
-52.0%
Debt / Equity
—
Net Cash
$61.3M
Return 1Y
+69.3%
Company profile
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting multiple myeloma and non-Hodgkin lymphomas. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- CEO
- Andrew J. Hirsch
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 150
- Headquarters
- Massachusetts
- Website
- c4therapeutics.com
Management & directors
- Reyno LeonardChief Medical Officer
- Hirsch AndrewPresident & CEO
- Adams KendraChief Financial Officer
- Boyle Scott NChief Business Officer
- Mahaney PaigeChief Scientific Officer
- Mossler MarkChief Accounting Officer
- Schick KellyChief People Officer
Roles derived from SEC Form 4 filings.
Earnings
CCCC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.2M↓ -15.0%
Diluted EPS-$0.20↓ -45.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$60.4M | -$82.1M | -$129.5M | -$139.0M | -$119.6M | -$115.2M |
| Net income | -$66.3M | -$83.9M | -$128.2M | -$132.5M | -$105.3M | -$105.0M |
| Diluted EPS | — | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
| Operating cash flow | -$67.2M | -$87.0M | -$105.9M | -$106.8M | -$65.2M | -$98.7M |
| Free cash flow | -$67.9M | -$88.2M | -$111.4M | -$108.5M | -$65.3M | -$99.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -179.4% | -416.6% | -669.8% | -336.1% | -320.5% |
| Net margin | — | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M | $15.4M | $5.2M | $7.2M | $6.5M | $11.2M | $11.0M | $6.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.4M | -$28.2M | -$37.7M | -$29.2M | -$28.5M | -$34.4M | -$23.1M | -$27.8M |
| Net income | -$17.7M | -$24.7M | -$34.6M | -$26.3M | -$26.0M | -$32.2M | -$20.5M | -$25.1M |
| Diluted EPS | -$0.26 | -$0.35 | -$0.50 | -$0.37 | -$0.37 | -$0.44 | -$0.09 | -$0.20 |
| Operating cash flow | -$5.0M | -$24.1M | -$17.9M | -$33.3M | -$12.1M | -$31.2M | -$22.1M | -$29.9M |
| Free cash flow | -$5.2M | -$24.1M | -$17.9M | -$33.3M | -$12.2M | -$31.6M | -$22.2M | -$30.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -178.6% | -183.9% | -728.4% | -402.9% | -441.0% | -306.4% | -210.1% | -451.6% |
| Net margin | -147.6% | -160.6% | -667.8% | -363.7% | -402.6% | -286.4% | -186.0% | -408.5% |
Company news
Jul 7, 2026
Jul 3, 2026
Jun 11, 2026
- 39d agoC4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2Dfinance.yahoo.com
- 39d agoC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Populationfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | REYNO LEONARD· Chief Medical Officer | Tax withholding | 7,397 | $4.06 | $30,031.82 | filing |
| 2026-07-10 | REYNO LEONARD· Chief Medical Officer | Option exercise | 15,325 | $0.00 | $0.00 | filing |
| 2026-07-01 | GROGAN DONNA ROY | Award | 3,341 | $4.34 | $14,499.94 | filing |
| 2026-07-01 | Anderson Kenneth Carl | Award | 2,650 | $4.34 | $11,501.00 | filing |
| 2026-06-01 | Anderson Kenneth Carl | Option exercise | 1,070 | $2.11 | $2,257.70 | filing |
| 2026-04-01 | GROGAN DONNA ROY | Award | 5,370 | $2.70 | $14,499.00 | filing |
| 2026-04-01 | Anderson Kenneth Carl | Award | 4,259 | $2.70 | $11,499.30 | filing |
| 2026-02-15 | Hirsch Andrew· President & CEO | Tax withholding | 9,057 | $1.89 | $17,117.73 | filing |
| 2026-02-15 | Hirsch Andrew· President & CEO | Option exercise | 20,400 | $0.00 | $0.00 | filing |
| 2026-02-14 | Hirsch Andrew· President & CEO | Tax withholding | 39,154 | $1.89 | $74,001.06 | filing |
| 2026-02-14 | REYNO LEONARD· Chief Medical Officer | Tax withholding | 16,579 | $1.89 | $31,334.31 | filing |
| 2026-02-14 | Adams Kendra· Chief Financial Officer | Tax withholding | 15,381 | $1.89 | $29,070.09 | filing |
| 2026-02-14 | Boyle Scott N· Chief Business Officer | Tax withholding | 7,269 | $1.89 | $13,738.41 | filing |
| 2026-02-14 | Schick Kelly· Chief People Officer | Tax withholding | 7,269 | $1.89 | $13,738.41 | filing |
| 2026-02-14 | Mossler Mark· Chief Accounting Officer | Tax withholding | 3,268 | $1.89 | $6,176.52 | filing |
| 2026-02-14 | Mahaney Paige· Chief Scientific Officer | Tax withholding | 2,446 | $1.89 | $4,622.94 | filing |
| 2026-02-14 | Boyle Scott N· Chief Business Officer | Option exercise | 20,950 | $0.00 | $0.00 | filing |
| 2026-02-14 | Adams Kendra· Chief Financial Officer | Option exercise | 30,950 | $0.00 | $0.00 | filing |
| 2026-02-14 | Hirsch Andrew· President & CEO | Option exercise | 81,725 | $0.00 | $0.00 | filing |
| 2026-02-14 | Mahaney Paige· Chief Scientific Officer | Option exercise | 7,050 | $0.00 | $0.00 | filing |
| 2026-02-14 | Mossler Mark· Chief Accounting Officer | Option exercise | 9,420 | $0.00 | $0.00 | filing |
| 2026-02-14 | Schick Kelly· Chief People Officer | Option exercise | 20,950 | $0.00 | $0.00 | filing |
| 2026-02-14 | REYNO LEONARD· Chief Medical Officer | Option exercise | 30,950 | $0.00 | $0.00 | filing |
| 2026-02-13 | Adams Kendra· Chief Financial Officer | Tax withholding | 1,863 | $1.89 | $3,521.07 | filing |
| 2026-02-13 | Boyle Scott N· Chief Business Officer | Tax withholding | 1,735 | $1.89 | $3,279.15 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.